Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRM (cardiac rhythm management) sales drive Medtronic's strong performance

This article was originally published in Clinica

Executive Summary

Medtronic's fourth-quarter sales were $27m better than estimates by analysts at Morgan Stanley. This was due largely to strong cardiac rhythm management sales, together with better-than-expected vascular sales, although these were still weak, the analysts said. Cardiac rhythm management sales were a record $2.94bn in the year and $832m in the quarter, up 13% and 18%, respectively. Traditional pacing sales were weak, but the company had strong sales of its InSync device for congestive heart failure, as well as better than expected sales of traditional ICD products, the analysts said. Medtronic's vascular unit sales were $206m in the quarter, down 16%, but up 10% sequentially, the company said.

You may also be interested in...



Former MiMedX Execs Convicted On Securities Fraud Charges

The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.

First-Of-Its-Kind Prostate Cancer Imaging Agent Approved By FDA

Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.

GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking

A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.

Topics

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel